This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
PRDM11 Polyclonal Antibody
catalog :
PA5-18111
quantity :
100 ug
price :
US 464.00
clonality :
polyclonal
host :
domestic goat
conjugate :
nonconjugated
reactivity :
human
application :
western blot, immunohistochemistry, immunohistochemistry - paraffin section
product information
Product Type :
Antibody
Product Name :
PRDM11 Polyclonal Antibody
Catalog # :
PA5-18111
Quantity :
100 ug
Price :
US 464.00
Clonality :
Polyclonal
Purity :
Ammonium sulfate precipitation
Host :
Goat
Reactivity :
Human
Applications :
Immunohistochemistry (Paraffin): 5 ug/mL, Western Blot: 2-3 ug/mL
Species :
Human
Isotype :
IgG
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
PRDM11 (PR/SET Domain 11) is a Protein Coding gene. Gene Ontology (GO) annotations related to this gene include nucleic acid binding and methyltransferase activity. May be involved in transcription regulation.
Immunogen :
Synthetic peptide sequence (LSEGRVRSGLCGG) corresponding to the C-terminus amino acids of PRDM11 (aa 499-511).
Format :
Liquid
Applications w/Dilutions :
Immunohistochemistry (Paraffin): 5 ug/mL, Western Blot: 2-3 ug/mL
Aliases :
8030443D09Rik; AA163972; Gm707; PFM8; PR domain 11; PR domain containing 11; PR domain-containing protein 11; PRDM11; PR-domain containing protein 11; RGD1305673
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments